Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
Status:
Completed
Trial end date:
2019-10-16
Target enrollment:
Participant gender:
Summary
This study is being conducted in patients with newly diagnosed breast cancer that will be
undergoing chemotherapy prior to surgery - neoadjuvant chemotherapy. The study involves
treatment with standard chemotherapy and a commonly used, FDA-approved, blood pressure drug
called propranolol (Inderal). The purposes of this study are to:
1. Determine the effect of propranolol plus chemotherapy on breast cancer cells as well as
the growth of blood vessels surrounding breast cancer cells.
2. Determine the side effect profile of propranolol and chemotherapy in patients with
breast cancer receiving neoadjuvant chemotherapy.
This research is being done because previous laboratory work has shown that propranolol may
decrease the ability for the blood vessels around breast cancer cells to grow, which may be
important in helping cancer cells grow. It also may reduce the likelihood for breast cancer
cells to spread. If changes are seen in the breast cancer cells and surrounding blood vessels
in this study, we will pan to evaluate whether propranolol decreases the likelihood of breast
cancer from recurring in future, later studies. All chemotherapy regimens used in this study
have been the standard of care for many years; however, the use of propranolol is being
researched along with the chemotherapy regimens.